Novartis

Novartis sees brighter sales future as R&D revamp continues
Novartis sees brighter sales future as R&D revamp continues
BioPharma Dive
Novartis
R&D
Flag link:
Novartis pays Legend $100M upfront to give solid tumor CAR-T the T-Charge treatment
Novartis pays Legend $100M upfront to give solid tumor CAR-T the T-Charge treatment
Fierce Biotech
Novartis
Legend Biotech
CAR-T
T-Charge
solid tumors
Flag link:
Novartis’ urticaria drug meets all endpoints in Phase III trials
Novartis’ urticaria drug meets all endpoints in Phase III trials
Clinical Trials Arena
Novartis
remibrutinib
chronic spontaneous urticaria
clinical trials
Flag link:
Novartis Inks Potential $1.3B Contract with Korean Biotech for Small Molecule
Novartis Inks Potential $1.3B Contract with Korean Biotech for Small Molecule
BioSpace
Novartis
Chong Kun Dang Pharmaceutical
small molecule drugs
Flag link:
FDA approves Novartis Cosentyx as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decade
FDA approves Novartis Cosentyx as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decade
Yahoo Finance
Novartis
Cosentyx
FDA
hidrad
Flag link:
Atrasentan data backs up Novartis’ $3.5bn Chinook deal
Atrasentan data backs up Novartis’ $3.5bn Chinook deal
Pharmaphorum
Novartis
IgA nephropathy
atrasentan
Chinook Therapeutics
Flag link:
Tricks and Treats as Biopharma’s Q3 Earnings Season Gets Underway
Tricks and Treats as Biopharma’s Q3 Earnings Season Gets Underway
BioSpace
earnings
Bristol Myers Squibb
Takeda
Novartis
Sanofi
Merck
Flag link:
Novartis claims ex-staffer jumped to Takeda with 'thousands' of sensitive files
Novartis claims ex-staffer jumped to Takeda with 'thousands' of sensitive files
Fierce Pharma
Novartis
Takeda
trade secrets
Flag link:
Novartis Beats Earnings Estimate in Q3, Raises Full-Year Guidance
Novartis Beats Earnings Estimate in Q3, Raises Full-Year Guidance
BioSpace
Novartis
earnings
Flag link:
Novartis Builds Case for Earlier Prostate Cancer Treatment with Phase III Data
Novartis Builds Case for Earlier Prostate Cancer Treatment with Phase III Data
BioSpace
ESMO
Novartis
prostate cancer
Pluvicto
radiopharmaceuticals
Flag link:
Novartis expats detail their health-tech spinoff DatosX
Novartis expats detail their health-tech spinoff DatosX
Medical Marketing and Media
Novartis
innovation
digital health
spinoffs
DatosX
Flag link:
Novartis cuts depression study, nearly erasing $210M Cadent acquisition from pipeline
Novartis cuts depression study, nearly erasing $210M Cadent acquisition from pipeline
Fierce Biotech
Novartis
Cadent Therapeutics
major depressive disorder
MIJ821
Flag link:
Novartis-backed AstronauTx heads off for Alzheimer's mission with $61M series A
Novartis-backed AstronauTx heads off for Alzheimer's mission with $61M series A
Fierce Biotech
AstronauTx
Novartis
Alzheimer's disease
Flag link:
Novartis Wins FDA Approval for Intravenous Cosentyx Formulation
Novartis Wins FDA Approval for Intravenous Cosentyx Formulation
BioSpace
Novartis
Cosentyx
FDA
ankylosing spondylitis
psoriatic arthritis
non-radiographic axial spondyloarthritis
Flag link:
Novartis' Sandoz dips on debut after lower than expected valuation
Novartis' Sandoz dips on debut after lower than expected valuation
Reuters
Novartis
Sandoz
spinoffs
Flag link:
Novartis eyes accelerated FDA approval for iptacopan across multiple indications
Novartis eyes accelerated FDA approval for iptacopan across multiple indications
Clinical Trials Arena
Novartis
clinical trials
iptacopan
IgA nephropathy
kidney disease
Flag link:
Adlai Nortye IPO gives old Novartis cancer drug new life
Adlai Nortye IPO gives old Novartis cancer drug new life
BioPharma Dive
Adlai Nortye
IPOs
Novartis
AN2025
head and neck cancer
solid tumors
Flag link:
Novartis confirms Sandoz spin-off for October 4, 2023
Novartis confirms Sandoz spin-off for October 4, 2023
Reuters
Novartis
Sandoz
spinoffs
Flag link:
Novartis eyes first-line use of Lutathera after trial win
Novartis eyes first-line use of Lutathera after trial win
Pharmaphorum
Novartis
radioligands
clinical trials
neuroendocrine tumors
Lutathera
Flag link:
FDA Regulatory Gauntlet Isn’t Getting Any Easier, Just Ask These Companies
FDA Regulatory Gauntlet Isn’t Getting Any Easier, Just Ask These Companies
BioSpace
FDA
ARS Pharmaceuticals
Novartis
Taysha
Alvotech
Intarcia
Flag link:

Pages